9900815-3
1902

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 491/04, 498/04, A61K 31/435, C07D 513/04

A1

(11) International Publication Number: **WO 98/45297**

(43) International Publication Date: 15 October 1998 (15.10.98)

(21) International Application Number: PCT/EP98/02136

(22) International Filing Date: 2 April 1998 (02.04.98)

(30) Priority Data:
97201045.8 8 April 1997 (08.04.97) EP
(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KENNIS, Ludo, Edmond, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). LOVE, Christopher, John [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). BISCHOFF, François, Paul [FR/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: 1,2,3,4–TETRAHYDRO–BENZOFURO[3,2–c]PYRIDINE DERIVATIVES

(57) Abstract



(I)

The present invention concerns the compounds of formula (I), the *N*–oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein each R^1 is independently hydrogen, halogen, C_{1-6}alkyl, nitro, hydroxy or C_{1-4}alkyloxy; Alk is C_{1-6}alkanediyl; n is 1 or 2; D is an optionally substituted mono–, bi– or tricyclic nitrogen containing heterocycle having central α_2–adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.